Consent Decree Looms As Philips Scores Q2 Growth In A Far From 'Business-As-Usual' Year
Embattled Healthtech Says Agile Operating Model And Restructuring Plans Remain On Track
Market uncertainties caused by macro events and the Respironics recall put their imprint on Philips’ second quarter of 2023, but the company secured high single-digit growth, reported robust order bookings and increased full-year revenue guidance.
